108985
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
舒芬太尼与地佐辛联合用于胰腺癌术后患者自控静脉镇痛：一项回顾性倾向评分匹配研究
Authors Huang Z , Li J, Xia Y , Li Q, Song X, Xu X, Luo Y
Received 10 April 2025
Accepted for publication 7 October 2025
Published 21 October 2025 Volume 2025:18 Pages 5523—5531
DOI https://doi.org/10.2147/JPR.S528699
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Amitabh Gulati
Zhihua Huang,1,* Jian Li,2,* Yimeng Xia,1 Qiang Li,1 Xiaoxing Song,1 Xiaoying Xu,1 Yan Luo1
1Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China; 2Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yan Luo, Department of Anaesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Huang Pu District, Shanghai, 200025, People’s Republic of China, Tel +86-21-64370045, Email ly11087@rjh.com.cn
Purpose: This study evaluated the efficacy and safety of patient-controlled intravenous analgesia (PCIA) regimen combining sufentanil and dezocine versus sufentanil alone for postoperative pain relief in pancreatic surgery patients.
Methods: We conducted a retrospective study comparing perioperative outcomes, the postoperative incidence of moderate-severe pain at rest and during coughing, and adverse effects in patients undergoing pancreatic surgery who received sufentanil (sufentanil group, n=247) versus a combination of sufentanil and dezocine (combination group, n=704) for PCIA. Propensity score matching (1:3) was performed to balance the groups.
Results: There were no significant differences in the demographic or perioperative outcomes between the two groups after matching. Within 48 hours after surgery, the incidence of moderate-severe pain at rest was significantly lower in the combination group (2.8%) compared to the sufentanil group (7.7%, P< 0.05). Similarly, pain during coughing was significantly higher in the sufentanil group (30.0%) than in the combination group (23.6%, P< 0.05). No significant differences were observed in adverse effects, including vomiting, hypotension, dizziness, or delirium during the first two postoperative days. The levels of sedation (LOS) were comparable on the first postoperative day, but a higher proportion of patients in the combination group were fully alert on the second day.
Conclusion: The combination of sufentanil and dezocine provides superior postoperative analgesia without increasing clinically relevant adverse effects, making it a promising option for pain management in pancreatic surgery patients. Further research is warranted to validate its routine clinical use.
Keywords: sufentanil, dezocine, patient-controlled intravenous analgesia, postoperative pain, pancreatic surgery, propensity score matching
1Department of Anesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China; 2Clinical Research Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yan Luo, Department of Anaesthesiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, Huang Pu District, Shanghai, 200025, People’s Republic of China, Tel +86-21-64370045, Email ly11087@rjh.com.cn
Purpose: This study evaluated the efficacy and safety of patient-controlled intravenous analgesia (PCIA) regimen combining sufentanil and dezocine versus sufentanil alone for postoperative pain relief in pancreatic surgery patients.
Methods: We conducted a retrospective study comparing perioperative outcomes, the postoperative incidence of moderate-severe pain at rest and during coughing, and adverse effects in patients undergoing pancreatic surgery who received sufentanil (sufentanil group, n=247) versus a combination of sufentanil and dezocine (combination group, n=704) for PCIA. Propensity score matching (1:3) was performed to balance the groups.
Results: There were no significant differences in the demographic or perioperative outcomes between the two groups after matching. Within 48 hours after surgery, the incidence of moderate-severe pain at rest was significantly lower in the combination group (2.8%) compared to the sufentanil group (7.7%, P< 0.05). Similarly, pain during coughing was significantly higher in the sufentanil group (30.0%) than in the combination group (23.6%, P< 0.05). No significant differences were observed in adverse effects, including vomiting, hypotension, dizziness, or delirium during the first two postoperative days. The levels of sedation (LOS) were comparable on the first postoperative day, but a higher proportion of patients in the combination group were fully alert on the second day.
Conclusion: The combination of sufentanil and dezocine provides superior postoperative analgesia without increasing clinically relevant adverse effects, making it a promising option for pain management in pancreatic surgery patients. Further research is warranted to validate its routine clinical use.
Keywords: sufentanil, dezocine, patient-controlled intravenous analgesia, postoperative pain, pancreatic surgery, propensity score matching